Nimotuzumab is another EGFR-targeting antibody, but it's carved out its own clinical niche distinct from Cetuximab — largely because of a meaningfully milder skin-toxicity profile, which matters a great deal in markets where dermatology support for managing severe rash side effects is limited or unavailable at the treating facility. It's used most commonly in head and neck cancers, certain brain tumors, and esophageal cancer, typically as part of a combined chemoradiation protocol rather than standalone.
- Approved indications: Head and neck squamous cell carcinoma, high-grade glioma (brain cancer), esophageal cancer
- Mechanism: Binds EGFR, blocking growth-signaling pathways in tumor cells with a moderate binding affinity that's specifically associated with reduced skin-toxicity compared to other anti-EGFR antibodies
- Combination therapy: Typically given alongside radiation therapy or chemoradiation, not as monotherapy
- Clinical differentiator: Significantly lower incidence of severe acneiform rash than Cetuximab — a genuine consideration for facilities without ready dermatology support
- Handling note: Short 4-hour room-temperature stability window once opened requires tighter administration-timing coordination at the point of care than most biologics in our catalogue
- Contraindication: Severe hypersensitivity to the product
- Caution population: Hepatic or renal impairment — closer monitoring recommended
- Restrictions: Not recommended in pregnancy
- Post-reconstitution handling: Must be administered within 4 hours if not refrigerated after preparation — a detail hospital pharmacy teams need built into their infusion scheduling
- Certification: WHO-GMP sourced manufacturing
- Batch-specific testing: EGFR-targeting binding validated per batch before release
- Product-specific guidance: Given its shorter post-reconstitution stability window compared to other EGFR-inhibitor biologics, we include clear handling-timeline documentation with every shipment for the receiving pharmacy team
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: In stock for export | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export (2–8°C)
- Coverage: Global, with steady demand from markets treating high volumes of head and neck cancer
- Tracking: Full shipment tracking included
- Institutional buyers: Hospital and distributor procurement support
- Positioning for facilities with limited dermatology access: Frequently recommended by our team as the preferred EGFR-inhibitor option for centers without dedicated dermatology support to manage severe rash-related side effects
- Unregistered markets: Named-patient supply pathway available
What is Nimotuzumab used for?
Treats head and neck cancer, certain brain tumors, and esophageal cancer, usually combined with radiation therapy.
Get Nimotuzumab price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
How is it different from Cetuximab?
It causes significantly less severe skin rash, making it a better fit for facilities without strong dermatology support.
Who supplies Nimotuzumab from India?
WHO-GMP certified manufacturer with full export documentation.
Can it be combined with radiation therapy?
Yes, it's typically used alongside radiation or chemoradiation protocols.
